Dermatologist inspecting a patient's skin

Routine NHS use of skin cancer drug recommended

NICE has recommended the routine NHS use of a new skin cancer drug, as an option after surgery for some patients with melanoma.

Final draft guidance on the drug (called nivolumab) was issued by NICE on February 12, 2021 with an appeal period now open until February 26, 2021.

Nivolumab was available for the past two years within the Cancer Drugs Fund, recommended for use as an option for the adjuvant treatment of completely resected melanoma in adults with lymph node involvement or metastatic disease.

This allowed for patients to access the drug while data on its effectiveness was being collected, in order to address significant clinical uncertainty.

Under these terms, its use was permitted in set circumstances but more data was required to be gathered before it could be considered for routine commissioning. This meant until recently, NICE had been unable to recommend the use of nivolumab in draft guidance.

Even now it has the data required to make the recommendation, NICE made clear reference to the fact the data from the Cancer Drugs Fund and key clinical trial were still relatively immature and so it was uncertain what impact nivolumab would have on life of time people lived for or by how much it increased overall survival rates.

Following consultation, the committee was persuaded that some of its preferred assumptions for estimating long-term survival of people who had been treated with nivolumab had been too conservative.

New analyses presented by the drug’s manufacturer showed that the most likely estimates of cost-effectiveness were within the range NICE considers a cost-effective use of NHS resources.

In response, the committee at NICE has now recommended the routine use of nivolumab as an option after surgery for some people with melanoma, subject to the drug manufacturer providing it according to the commercial arrangement agreed with the NHS.

NHE July/August 21

NHE July/August 21

Prioritising staff wellbeing

NHE’s July/August 2021 edition focuses on some of the key, defining aspects of a successful, supported health service: Mental Health & Workforce. Elsewhere, we take on the incredibly topical Infection Prevention and address the role which Pharma will play in both our NHS and wider health environment.


View all videos
National Health Executive Presents

National Health Executive Presents

NHE365 Virtual Festival: Net-Zero NHS

As was outlined by Sir Simon Stevens when the NHS announced their green plans back in 2020, 5,700 lives could be saved each year by improved air quality. Even more could see their overall health improve and be in a position to self-manage their conditions, rather than requiring NHS treatment. Covid-19 has already left the NHS with a sizeable treatment backlog, so anything which can be done to improve patient health and reduce demand is beneficial for all.

Working together, we can help the NHS realise its green ambitions as per the Net-Zero National Health Service report and its ambitious 2040 target. Join us on August 25, 2021 for our Net-Zero NHS event, where we will be joined by health sector leaders and innovators for a day of sharing best practice and networking.

Finger on the Pulse

Ep 14. Health messaging is a science, Professor Craig Jackson

On Episode 14 of NHE's Finger on the Pulse podcast, we're joined by Professor Craig Jackson, Professor of Occupational Health Psychology
Birmingham City University to discuss the coronavirus pandemic, the health messaging around it and how those in power have missed a trick by overlooking the key role of psychology in informing the public of restrictions, measures and the ever-changing situation

More articles...

View all